Qi Lai

Johns Hopkins University

Papers

1

Total Citations

9

H-Index

1

About

Qi Lai has made significant contributions to the field of non-invasive cancer diagnostics, with a primary focus on leveraging small non-coding RNAs for early lung cancer detection. In their landmark 2021 study, Lai introduced a cost-effective, non-invasive test using plasma protein functional effector sncRNAs (pfeRNAs) to differentiate benign, suspicious, and malignant pulmonary nodules—a critical challenge in early-stage lung cancer management. This work, which has garnered 9 citations, offers a promising alternative to invasive biopsies, potentially reducing unnecessary procedures and enabling timely interventions. By identifying pfeRNAs as robust biomarkers, Lai’s research bridges a key gap in precision oncology, emphasizing accessibility and patient comfort. Their contributions not only advance the understanding of RNA biology in cancer but also hold tangible clinical promise for improving diagnostic accuracy. Lai’s innovative approach underscores a commitment to translating molecular insights into practical, life-saving tools, positioning them as a rising voice in the intersection of genomics and translational medicine.

Research Focus

Key Achievements

1
H-Index
1
Papers
9
Total Citations
9
Avg Citations/Paper
🏆 Most Cited Paper
A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones
9 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Johns Hopkins University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago